ES2764282T3 - Composición de microbiota, como marcador de sensibilidad a la quimioterapia y uso de moduladores microbianos (prebióticos, probióticos o simbióticos) para mejorar la eficacia de un tratamiento contra el cáncer - Google Patents

Info

Publication number

ES2764282T3

ES2764282T3 ES14812648T ES14812648T ES2764282T3 ES 2764282 T3 ES2764282 T3 ES 2764282T3 ES 14812648 T ES14812648 T ES 14812648T ES 14812648 T ES14812648 T ES 14812648T ES 2764282 T3 ES2764282 T3 ES 2764282T3

Authority

ES

Spain

Prior art keywords

ctx

cells

mice

composition

bacteria

Prior art date

2013-11-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 141
• 238000011282 treatment Methods 0.000 title claims abstract description 127
• 239000000203 mixture Substances 0.000 title claims abstract description 115
• 201000011510 cancer Diseases 0.000 title claims abstract description 71
• 239000006041 probiotic Substances 0.000 title claims description 43
• 235000018291 probiotics Nutrition 0.000 title claims description 43
• 238000002512 chemotherapy Methods 0.000 title description 274
• 241000736262 Microbiota Species 0.000 title description 26
• 235000013406 prebiotics Nutrition 0.000 title description 8
• 230000000813 microbial effect Effects 0.000 title description 7
• 239000003550 marker Substances 0.000 title description 2
• 230000035945 sensitivity Effects 0.000 title description 2
• 241000894006 Bacteria Species 0.000 claims abstract description 116
• 241000194029 Enterococcus hirae Species 0.000 claims abstract description 70
• 230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 44
• 241001468157 Lactobacillus johnsonii Species 0.000 claims abstract description 38
• 241000894007 species Species 0.000 claims description 35
• 241000227342 Candidatus Arthromitus sp. SFB-mouse Species 0.000 claims description 33
• 239000002246 antineoplastic agent Substances 0.000 claims description 32
• 230000000529 probiotic effect Effects 0.000 claims description 30
• 230000007140 dysbiosis Effects 0.000 claims description 24
• 230000003115 biocidal effect Effects 0.000 claims description 23
• 229940127089 cytotoxic agent Drugs 0.000 claims description 21
• 208000027244 Dysbiosis Diseases 0.000 claims description 20
• 244000005700 microbiome Species 0.000 claims description 17
• 241000927512 Barnesiella Species 0.000 claims description 14
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 14
• 241000605894 Porphyromonas Species 0.000 claims description 14
• 241000862469 Holdemania Species 0.000 claims description 13
• 239000002671 adjuvant Substances 0.000 claims description 13
• 229960004397 cyclophosphamide Drugs 0.000 claims description 13
• 230000002163 immunogen Effects 0.000 claims description 13
• 239000012634 fragment Substances 0.000 claims description 11
• 229940022399 cancer vaccine Drugs 0.000 claims description 6
• 238000001228 spectrum Methods 0.000 claims description 4
• 238000007920 subcutaneous administration Methods 0.000 claims description 4
• 238000007918 intramuscular administration Methods 0.000 claims description 2
• 239000012646 vaccine adjuvant Substances 0.000 claims 1
• 229940124931 vaccine adjuvant Drugs 0.000 claims 1
• 208000001088 cerebrotendinous xanthomatosis Diseases 0.000 description 212
• 241000699670 Mus sp. Species 0.000 description 176
• 210000004027 cell Anatomy 0.000 description 99
• 239000003242 anti bacterial agent Substances 0.000 description 78
• 229940088710 antibiotic agent Drugs 0.000 description 71
• 210000001744 T-lymphocyte Anatomy 0.000 description 68
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 57
• 230000001580 bacterial effect Effects 0.000 description 56
• 238000002474 experimental method Methods 0.000 description 53
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 50
• 108010059993 Vancomycin Proteins 0.000 description 49
• 229960003165 vancomycin Drugs 0.000 description 49
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 49
• 244000005709 gut microbiome Species 0.000 description 48
• 230000004044 response Effects 0.000 description 47
• 238000000034 method Methods 0.000 description 39
• 241001465754 Metazoa Species 0.000 description 33
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 32
• 230000004614 tumor growth Effects 0.000 description 32
• 210000000813 small intestine Anatomy 0.000 description 29
• 230000001093 anti-cancer Effects 0.000 description 27
• 239000011780 sodium chloride Substances 0.000 description 26
• 210000004988 splenocyte Anatomy 0.000 description 26
• 210000000952 spleen Anatomy 0.000 description 25
• 210000004443 dendritic cell Anatomy 0.000 description 24
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 24
• 102000013691 Interleukin-17 Human genes 0.000 description 23
• 108050003558 Interleukin-17 Proteins 0.000 description 23
• 241000699666 Mus <mouse, genus> Species 0.000 description 23
• 210000003405 ileum Anatomy 0.000 description 22
• 230000028993 immune response Effects 0.000 description 22
• 239000000523 sample Substances 0.000 description 22
• 230000000968 intestinal effect Effects 0.000 description 21
• 108090000623 proteins and genes Proteins 0.000 description 21
• 238000002560 therapeutic procedure Methods 0.000 description 21
• 241000193403 Clostridium Species 0.000 description 20
• 108010078777 Colistin Proteins 0.000 description 19
• 229960003346 colistin Drugs 0.000 description 19
• 210000004877 mucosa Anatomy 0.000 description 19
• JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 19
• XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 19
• KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 19
• 241000192125 Firmicutes Species 0.000 description 18
• 230000000694 effects Effects 0.000 description 18
• 241000588724 Escherichia coli Species 0.000 description 17
• 241000186660 Lactobacillus Species 0.000 description 17
• 206010039491 Sarcoma Diseases 0.000 description 17
• 241000606210 Parabacteroides distasonis Species 0.000 description 16
• 210000003608 fece Anatomy 0.000 description 16
• 238000000684 flow cytometry Methods 0.000 description 16
• 238000003753 real-time PCR Methods 0.000 description 16
• 230000000259 anti-tumor effect Effects 0.000 description 15
• 229960004679 doxorubicin Drugs 0.000 description 15
• 238000000338 in vitro Methods 0.000 description 15
• 238000002347 injection Methods 0.000 description 15
• 239000007924 injection Substances 0.000 description 15
• 229940100198 alkylating agent Drugs 0.000 description 14
• 239000002168 alkylating agent Substances 0.000 description 14
• 210000004400 mucous membrane Anatomy 0.000 description 14
• 238000012175 pyrosequencing Methods 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 13
• 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 13
• 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 13
• 239000012472 biological sample Substances 0.000 description 13
• 230000001404 mediated effect Effects 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 238000002965 ELISA Methods 0.000 description 12
• 102100029424 Nucleotide-binding oligomerization domain-containing protein 1 Human genes 0.000 description 12
• 210000000068 Th17 cell Anatomy 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 12
• 210000001198 duodenum Anatomy 0.000 description 12
• 230000028327 secretion Effects 0.000 description 12
• 230000003393 splenic effect Effects 0.000 description 12
• 229960005322 streptomycin Drugs 0.000 description 12
• 238000012546 transfer Methods 0.000 description 12
• 102000004127 Cytokines Human genes 0.000 description 11
• 108090000695 Cytokines Proteins 0.000 description 11
• 241000194032 Enterococcus faecalis Species 0.000 description 11
• 101001125032 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 1 Proteins 0.000 description 11
• 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 11
• 108010058846 Ovalbumin Proteins 0.000 description 11
• 238000000692 Student's t-test Methods 0.000 description 11
• 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 11
• 230000014509 gene expression Effects 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 238000001114 immunoprecipitation Methods 0.000 description 11
• 230000001965 increasing effect Effects 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 108020004465 16S ribosomal RNA Proteins 0.000 description 10
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 10
• 108020004414 DNA Proteins 0.000 description 10
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 10
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 10
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 10
• 229960000723 ampicillin Drugs 0.000 description 10
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
• 239000000969 carrier Substances 0.000 description 10
• 230000001413 cellular effect Effects 0.000 description 10
• 230000007423 decrease Effects 0.000 description 10
• 238000012353 t test Methods 0.000 description 10
• 241000186000 Bifidobacterium Species 0.000 description 9
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 9
• 102100022338 Integrin alpha-M Human genes 0.000 description 9
• 238000009825 accumulation Methods 0.000 description 9
• 230000002950 deficient Effects 0.000 description 9
• 239000002158 endotoxin Substances 0.000 description 9
• 238000011081 inoculation Methods 0.000 description 9
• 229940039696 lactobacillus Drugs 0.000 description 9
• 229920006008 lipopolysaccharide Polymers 0.000 description 9
• 238000007619 statistical method Methods 0.000 description 9
• 239000006228 supernatant Substances 0.000 description 9
• 229960005486 vaccine Drugs 0.000 description 9
• 206010070545 Bacterial translocation Diseases 0.000 description 8
• 102100022297 Integrin alpha-X Human genes 0.000 description 8
• 108090001005 Interleukin-6 Proteins 0.000 description 8
• 102000004889 Interleukin-6 Human genes 0.000 description 8
• 240000006024 Lactobacillus plantarum Species 0.000 description 8
• 230000005867 T cell response Effects 0.000 description 8
• WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 8
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 230000007375 bacterial translocation Effects 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 238000001574 biopsy Methods 0.000 description 8
• 229940044683 chemotherapy drug Drugs 0.000 description 8
• 210000001072 colon Anatomy 0.000 description 8
• 229960002182 imipenem Drugs 0.000 description 8
• ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 8
• 230000036039 immunity Effects 0.000 description 8
• 210000001165 lymph node Anatomy 0.000 description 8
• 229940092253 ovalbumin Drugs 0.000 description 8
• 230000001717 pathogenic effect Effects 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• 230000005945 translocation Effects 0.000 description 8
• 229920001817 Agar Polymers 0.000 description 7
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 7
• 206010009944 Colon cancer Diseases 0.000 description 7
• 241000605980 Faecalibacterium prausnitzii Species 0.000 description 7
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 7
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 7
• 241001112693 Lachnospiraceae Species 0.000 description 7
• 241000692843 Porphyromonadaceae Species 0.000 description 7
• 241000186569 [Clostridium] leptum Species 0.000 description 7
• 239000008272 agar Substances 0.000 description 7
• 208000029742 colonic neoplasm Diseases 0.000 description 7
• 239000003814 drug Substances 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 210000000936 intestine Anatomy 0.000 description 7
• 210000003071 memory t lymphocyte Anatomy 0.000 description 7
• 229960001756 oxaliplatin Drugs 0.000 description 7
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 7
• 238000001356 surgical procedure Methods 0.000 description 7
• 230000009885 systemic effect Effects 0.000 description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• 241000701474 Alistipes Species 0.000 description 6
• 241000606125 Bacteroides Species 0.000 description 6
• 241000193468 Clostridium perfringens Species 0.000 description 6
• 241001185600 Gemmiger Species 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 241000282414 Homo sapiens Species 0.000 description 6
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 6
• 108090000174 Interleukin-10 Proteins 0.000 description 6
• 241000186604 Lactobacillus reuteri Species 0.000 description 6
• 102000016943 Muramidase Human genes 0.000 description 6
• 108010014251 Muramidase Proteins 0.000 description 6
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 6
• 229930193140 Neomycin Natural products 0.000 description 6
• 102100038081 Signal transducer CD24 Human genes 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 229960000603 cefalotin Drugs 0.000 description 6
• XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 6
• 235000015872 dietary supplement Nutrition 0.000 description 6
• 230000004069 differentiation Effects 0.000 description 6
• 230000002349 favourable effect Effects 0.000 description 6
• 238000009169 immunotherapy Methods 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 238000011227 neoadjuvant chemotherapy Methods 0.000 description 6
• 229960004927 neomycin Drugs 0.000 description 6
• 210000003134 paneth cell Anatomy 0.000 description 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
• 230000010287 polarization Effects 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 6
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
• 241000605059 Bacteroidetes Species 0.000 description 5
• 210000000447 Th1 cell Anatomy 0.000 description 5
• 102000002689 Toll-like receptor Human genes 0.000 description 5
• 108020000411 Toll-like receptor Proteins 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 229940045799 anthracyclines and related substance Drugs 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 238000001815 biotherapy Methods 0.000 description 5
• 238000009566 cancer vaccine Methods 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 229940032049 enterococcus faecalis Drugs 0.000 description 5
• 230000002550 fecal effect Effects 0.000 description 5
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
• 239000013641 positive control Substances 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 230000001737 promoting effect Effects 0.000 description 5
• 238000011002 quantification Methods 0.000 description 5
• 238000001959 radiotherapy Methods 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 230000009261 transgenic effect Effects 0.000 description 5
• 238000002255 vaccination Methods 0.000 description 5
• 235000013618 yogurt Nutrition 0.000 description 5
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
• 108091093088 Amplicon Proteins 0.000 description 4
• 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
• 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
• 206010010356 Congenital anomaly Diseases 0.000 description 4
• 108010051219 Cre recombinase Proteins 0.000 description 4
• 108010065637 Interleukin-23 Proteins 0.000 description 4
• 102000013264 Interleukin-23 Human genes 0.000 description 4
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 230000005975 antitumor immune response Effects 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 239000006285 cell suspension Substances 0.000 description 4
• 230000001010 compromised effect Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000029087 digestion Effects 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 235000013376 functional food Nutrition 0.000 description 4
• 210000002175 goblet cell Anatomy 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 4
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 4
• 201000005249 lung adenocarcinoma Diseases 0.000 description 4
• 229960000274 lysozyme Drugs 0.000 description 4
• 235000010335 lysozyme Nutrition 0.000 description 4
• 239000004325 lysozyme Substances 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 238000000513 principal component analysis Methods 0.000 description 4
• 238000013207 serial dilution Methods 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 108060005980 Collagenase Proteins 0.000 description 3
• 102000029816 Collagenase Human genes 0.000 description 3
• 241001464948 Coprococcus Species 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• 101710113436 GTPase KRas Proteins 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
• 102000000588 Interleukin-2 Human genes 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 101100182715 Mus musculus Ly6c2 gene Proteins 0.000 description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
• 241000605947 Roseburia Species 0.000 description 3
• 230000029662 T-helper 1 type immune response Effects 0.000 description 3
• 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 210000000612 antigen-presenting cell Anatomy 0.000 description 3
• 229940034982 antineoplastic agent Drugs 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 235000013361 beverage Nutrition 0.000 description 3
• 239000006161 blood agar Substances 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 229960002424 collagenase Drugs 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
• 230000008029 eradication Effects 0.000 description 3
• 235000013350 formula milk Nutrition 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 238000001794 hormone therapy Methods 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 238000003125 immunofluorescent labeling Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 210000004347 intestinal mucosa Anatomy 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 210000002429 large intestine Anatomy 0.000 description 3
• 208000037841 lung tumor Diseases 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 231100000590 oncogenic Toxicity 0.000 description 3
• 230000002246 oncogenic effect Effects 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 229910052697 platinum Inorganic materials 0.000 description 3
• 230000037452 priming Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 210000005212 secondary lymphoid organ Anatomy 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• TZZNWMJZDWYJAZ-UHFFFAOYSA-N 2-(4-oxo-2-phenylchromen-8-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 TZZNWMJZDWYJAZ-UHFFFAOYSA-N 0.000 description 2
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 239000012103 Alexa Fluor 488 Substances 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
• 241001430149 Clostridiaceae Species 0.000 description 2
• 241001532560 Clostridium sp. Clone-40 Species 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 102000000541 Defensins Human genes 0.000 description 2
• 108010002069 Defensins Proteins 0.000 description 2
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
• 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 2
• 102000016911 Deoxyribonucleases Human genes 0.000 description 2
• 108010053770 Deoxyribonucleases Proteins 0.000 description 2
• MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
• 241000194033 Enterococcus Species 0.000 description 2
• 241000609971 Erysipelotrichaceae Species 0.000 description 2
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 2
• 101000733257 Homo sapiens Rho guanine nucleotide exchange factor 28 Proteins 0.000 description 2
• 241000341655 Human papillomavirus type 16 Species 0.000 description 2
• 238000012404 In vitro experiment Methods 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 241000186871 Lactobacillus murinus Species 0.000 description 2
• 102000013519 Lipocalin-2 Human genes 0.000 description 2
• 108010051335 Lipocalin-2 Proteins 0.000 description 2
• 102000043131 MHC class II family Human genes 0.000 description 2
• 108091054438 MHC class II family Proteins 0.000 description 2
• 101150053046 MYD88 gene Proteins 0.000 description 2
• ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
• 108700002045 Nod2 Signaling Adaptor Proteins 0.000 description 2
• 101150083031 Nod2 gene Proteins 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 241000425347 Phyla <beetle> Species 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 238000011530 RNeasy Mini Kit Methods 0.000 description 2
• 238000011529 RT qPCR Methods 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 102100033204 Rho guanine nucleotide exchange factor 28 Human genes 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 108700012920 TNF Proteins 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
• 150000001541 aziridines Chemical class 0.000 description 2
• 244000052616 bacterial pathogen Species 0.000 description 2
• 230000002146 bilateral effect Effects 0.000 description 2
• 210000000013 bile duct Anatomy 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
• 229960004117 capecitabine Drugs 0.000 description 2
• 229960005243 carmustine Drugs 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000002354 daily effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• 230000017214 establishment of T cell polarity Effects 0.000 description 2
• 230000003203 everyday effect Effects 0.000 description 2
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 235000012041 food component Nutrition 0.000 description 2
• 230000007407 health benefit Effects 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000010166 immunofluorescence Methods 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 210000005027 intestinal barrier Anatomy 0.000 description 2
• 230000007358 intestinal barrier function Effects 0.000 description 2
• 230000003870 intestinal permeability Effects 0.000 description 2
• 238000010212 intracellular staining Methods 0.000 description 2
• 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 2
• 230000002601 intratumoral effect Effects 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 229960002247 lomustine Drugs 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 210000005210 lymphoid organ Anatomy 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 201000006512 mast cell neoplasm Diseases 0.000 description 2
• 208000006971 mastocytoma Diseases 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 238000007427 paired t-test Methods 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 102000007863 pattern recognition receptors Human genes 0.000 description 2
• 108010089193 pattern recognition receptors Proteins 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 238000002733 pharmacodynamic assay Methods 0.000 description 2
• 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
• 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 238000003906 pulsed field gel electrophoresis Methods 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 208000019465 refractory cytopenia of childhood Diseases 0.000 description 2
• 210000003289 regulatory T cell Anatomy 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 102200146742 rs2066844 Human genes 0.000 description 2
• 102200146596 rs2066845 Human genes 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 239000013049 sediment Substances 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 210000004989 spleen cell Anatomy 0.000 description 2
• 230000001954 sterilising effect Effects 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 150000004905 tetrazines Chemical class 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000002476 tumorcidal effect Effects 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
• 241001156739 Actinobacteria <phylum> Species 0.000 description 1
• 206010001488 Aggression Diseases 0.000 description 1
• 239000012114 Alexa Fluor 647 Substances 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 241000692822 Bacteroidales Species 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
• 101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 1
• 241000589876 Campylobacter Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102100026089 Caspase recruitment domain-containing protein 9 Human genes 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
• 108010072220 Cyclophilin A Proteins 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• 238000007400 DNA extraction Methods 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 241001143779 Dorea Species 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 241001326278 Enterococcus faecalis JH2-2 Species 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 241001288713 Escherichia coli MC1061 Species 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 241001608234 Faecalibacterium Species 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 241000605909 Fusobacterium Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
• 206010061968 Gastric neoplasm Diseases 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
• 206010053759 Growth retardation Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000983508 Homo sapiens Caspase recruitment domain-containing protein 9 Proteins 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
• 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
• 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 102100025323 Integrin alpha-1 Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 102100030703 Interleukin-22 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 125000000241 L-isoleucino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@@](C([H])([H])[H])(C(C([H])([H])[H])([H])[H])[H] 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 102100033467 L-selectin Human genes 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 108010052014 Liberase Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 229930191564 Monensin Natural products 0.000 description 1
• GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
• 206010028116 Mucosal inflammation Diseases 0.000 description 1
• 201000010927 Mucositis Diseases 0.000 description 1
• 101000998145 Mus musculus Interleukin-17A Proteins 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 108700002046 Nod1 Signaling Adaptor Proteins 0.000 description 1
• 101150005821 Nod1 gene Proteins 0.000 description 1
• 108010075205 OVA-8 Proteins 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 241000209094 Oryza Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 101150056612 PPIA gene Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 241000192001 Pediococcus Species 0.000 description 1
• 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
• 101710111198 Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 241000192142 Proteobacteria Species 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
• 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
• 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
• 108010079723 Shiga Toxin Proteins 0.000 description 1
• 231100000632 Spindle poison Toxicity 0.000 description 1
• 241000589970 Spirochaetales Species 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 230000037453 T cell priming Effects 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 230000030429 T-helper 17 type immune response Effects 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
• 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
• 241000589886 Treponema Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• IJHHEHHPHVHXNY-UHFFFAOYSA-N acetic acid;2-phenylchromen-4-one Chemical class CC(O)=O.O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 IJHHEHHPHVHXNY-UHFFFAOYSA-N 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 210000005006 adaptive immune system Anatomy 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 238000011226 adjuvant chemotherapy Methods 0.000 description 1
• 230000000240 adjuvant effect Effects 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 230000009603 aerobic growth Effects 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000016571 aggressive behavior Effects 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• 230000009604 anaerobic growth Effects 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 238000011394 anticancer treatment Methods 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
• 229960001372 aprepitant Drugs 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
• 238000007681 bariatric surgery Methods 0.000 description 1
• 210000004082 barrier epithelial cell Anatomy 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 229960001467 bortezomib Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 238000012754 cardiac puncture Methods 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000035572 chemosensitivity Effects 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 229960000928 clofarabine Drugs 0.000 description 1
• WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 230000004736 colon carcinogenesis Effects 0.000 description 1
• 230000001332 colony forming effect Effects 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000011254 conventional chemotherapy Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000010219 correlation analysis Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 229950002389 diaziquone Drugs 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
• 230000035622 drinking Effects 0.000 description 1
• 239000003651 drinking water Substances 0.000 description 1
• 235000020188 drinking water Nutrition 0.000 description 1
• 230000002183 duodenal effect Effects 0.000 description 1
• 235000006694 eating habits Nutrition 0.000 description 1
• BNFRJXLZYUTIII-UHFFFAOYSA-N efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 1
• 229960000925 efaproxiral Drugs 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 230000004890 epithelial barrier function Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960000752 etoposide phosphate Drugs 0.000 description 1
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000001808 exosome Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 235000021107 fermented food Nutrition 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 150000005699 fluoropyrimidines Chemical class 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• 239000005417 food ingredient Substances 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 231100000001 growth retardation Toxicity 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 230000024949 interleukin-17 production Effects 0.000 description 1
• 108010074108 interleukin-21 Proteins 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
• 230000003871 intestinal function Effects 0.000 description 1
• 230000004609 intestinal homeostasis Effects 0.000 description 1
• 238000009263 intestinal permeability test Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 229940001882 lactobacillus reuteri Drugs 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000007477 logistic regression Methods 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 208000018883 loss of balance Diseases 0.000 description 1
• 230000004758 lung carcinogenesis Effects 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
• BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
• 229960003439 mebendazole Drugs 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000021039 metastatic melanoma Diseases 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 230000003641 microbiacidal effect Effects 0.000 description 1
• 244000005706 microflora Species 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 1
• 229950005967 mitozolomide Drugs 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 229960005358 monensin Drugs 0.000 description 1
• GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 230000004682 mucosal barrier function Effects 0.000 description 1
• BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
• APNPVBXEWGCCLU-QNRZBPGKSA-N mycomycin Chemical compound OC(=O)C\C=C\C=C/C=C=CC#CC#C APNPVBXEWGCCLU-QNRZBPGKSA-N 0.000 description 1
• 230000001400 myeloablative effect Effects 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 229950007221 nedaplatin Drugs 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 230000005853 oncogenic activation Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 210000001986 peyer's patch Anatomy 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 238000005498 polishing Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 229940034080 provenge Drugs 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 229960004432 raltitrexed Drugs 0.000 description 1
• 238000010807 real-time PCR kit Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000979 retarding effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 102200146925 rs2066842 Human genes 0.000 description 1
• 102200098764 rs4986790 Human genes 0.000 description 1
• 102200098513 rs4986791 Human genes 0.000 description 1
• 229960005399 satraplatin Drugs 0.000 description 1
• 190014017285 satraplatin Chemical compound 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 241001464786 segmented filamentous bacterium Species 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229960000714 sipuleucel-t Drugs 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 230000002311 subsequent effect Effects 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000007761 synergistic anti-cancer Effects 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 229940021747 therapeutic vaccine Drugs 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 210000002303 tibia Anatomy 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
• 229960001082 trimethoprim Drugs 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
• 190014017283 triplatin tetranitrate Chemical compound 0.000 description 1
• 229950002860 triplatin tetranitrate Drugs 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 229910021642 ultra pure water Inorganic materials 0.000 description 1
• 239000012498 ultrapure water Substances 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 229960000653 valrubicin Drugs 0.000 description 1
• ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
• 239000004066 vascular targeting agent Substances 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960000922 vinflunine Drugs 0.000 description 1
• NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1